Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY004 (also known as KY1104) is a topical microbicide combination product under development by KYDES Pharmaceuticals for the prevention of HIV infection in high-risk individuals. The product is designed for vaginal administration and is being explored in multiple delivery formats, including gels, tablets, films, and rings. Its mechanism of action utilizes a dual-agent approach: one component is designed to reduce viral integration into the host genome, while the other inhibits viral replication. This combination strategy aims to provide a robust barrier against HIV transmission at the site of entry by targeting two distinct stages of the viral life cycle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KY004.